Holen Sie sich die Stockscreener-App
73.00
1.64%
1.18
Handel nachbörslich:
73.11
0.11
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca (AZN) Veteran Joins Perrigo Leadership Team | AZN St - GuruFocus
Hydrogel-based Drug Delivery System Market Top Companies Study - openPR.com
Transcript : AstraZeneca PLC Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 - marketscreener.com
AZN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm - ACCESS Newswire
AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment - Yahoo
M42 Partners with AstraZeneca, Sophia Genetics for Liquid Biopsy Testing in UAE - marketscreener.com
AstraZeneca: Enhertu promising against breast cancer - marketscreener.com
AstraZeneca (AZN) Reports Promising Phase 3 Results for Enhertu and Perjeta Combo - GuruFocus
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Nasdaq
AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer (AZN:NASDAQ) - Seeking Alpha
AstraZeneca (AZN) Considered for Potential Pharma Collaborations | AZN Stock News - GuruFocus
astrazeneca announces total voting rights update for may 2025 By Investing.com - Investing.com India
astrazeneca reports block listing interim review for share schemes - Investing.com
astrazeneca reports block listing interim review for share schemes By Investing.com - Investing.com UK
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO - Benzinga
AstraZeneca (AZN) Highlights Encouraging Enhertu Results in Breast Cancer Trial | AZN Stock News - GuruFocus
Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study - Bloomberg
AstraZeneca (AZN) Highlights Success in Breast Cancer Trial with Camizestrant | AZN Stock News - GuruFocus
AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com
AstraZeneca: camizestrant effective in breast cancer - marketscreener.com
AstraZeneca Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg.com
AstraZeneca - Britannica
AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit
ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6 - insights.citeline.com
PRESS DIGEST- Financial TimesJune 2 - marketscreener.com
AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials - GuruFocus
AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus
AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boo - GuruFocus
AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive
AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com
AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News
AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters
Danaher Partners With AstraZeneca to Support Precision Medicine - Yahoo Finance
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com
Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com
AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance
AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360
Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha
Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
Responsible care and use of animals in research - AstraZeneca
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance
Transcript : AstraZeneca PLCSpecial Call - marketscreener.com
AstraZeneca and Global Transparency - AstraZeneca
Ethics and Compliance - AstraZeneca
Nature - AstraZeneca
Inclusion and diversity - AstraZeneca
Community investment - AstraZeneca
Health Equity - AstraZeneca
AstraZeneca (AZN) Collaborates on Major AI Infrastructure in Swe - GuruFocus
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47% - MSN
AstraZeneca (AZN) Executive Joins Rapid Micro Biosystems' Board | AZN Stock News - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):